Mergers and Acquisitions
Raytheon Could Rally to the $230 Area in the Months Ahead - How to Buy It Now
Let's review the charts and indicators to see what they are showing today.
Possible M&A Surrounds These 3 Stocks
M&A activity has generally slowed.
The Cannabis Sector and Its Dot-Com Like Meltdown
Black-market vaping has made the entire cannabis group toxic.
Jim Cramer: How Iger and Benioff Let Twitter Get Away
Both are proud they dodged the Twitter bullet. But, in retrospect, was it really a bullet?
Fed Finally Gets It, Calling AT&T and Microsoft Delivers: Market Recon
A dividend hike and a big buyback authorization by Mr. Softee should produce value for shareholders.
I Have a Solution to Adobe's Growth Problem: DocuSign
The cloud stock's results weren't great, but were nothing close to the FedEx disaster.
VMware Shows New Strength, But Wait for a Dip or Retest to Buy
After a sprint higher in the IT company's shares in recent days, traders and investors might do well to wait for a temporary pullback to pick up the stock.
A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Palo Alto Networks Scoops Up Smaller Players, Smack Talks Competition
The cybersecurity name fired off some punches at the competition and picked up another bolt-on acquisition amid earnings.
Palo Alto Networks Surges, but Its Close Is More Important
Shares of the provider of network security platforms could bump into a resistance zone after a strong start.
Otezla Price Under Microscope -- but Look Closely and It Checks Out
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
M&A Appetite in Pharma Has Proved Potent: Chart of the Day
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
Broader Market Drags Affecting Salesforce Could Drive Buying Opportunity
CRM shouldn't be sagging with the broader tech sector.
VMware Stock: Screaming Buy or Screaming 'Death Cross'?
I see VMW trading in the high $130s and my engine gets running.
A Pair of Rare Disease Biotech Concerns Worth a Good Look
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
Salesforce Stock Surges as Cloud King Status Is Cemented
Salesforce is characteristically sustaining strength despite a heap of headwinds.
Time to Bend My Rules on Viacom by Buying This Sell-Off
Let's go back again to charts of VIAB.
Nvidia Surges on Better-Than-Feared Earnings, Stemming Slide in Semiconductors
Nvidia's second-quarter profits were well below its year-ago earnings but were nicely ahead of analyst expectations.
Tilray Stock Gains Ahead of Highly Anticipated Earnings Release
Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.
Keurig Dr Pepper Likely to Settle Into Sideways Pattern
Sellers of the beverage company's shares have been acting more aggressively than buyers in recent weeks.
Stay Tuned on Viacom-CBS Deal
A drop in shares doesn't necessarily mean it's time to turn the channel on Viacom, as details of expected merger with CBS will prove 'paramount.'
It's 'Showtime' for Viacom
Armed with Showtime, lots of cartoons and other mainstream shows, the CBS/Viacom merger appears to fit in between Disney Plus' family-friendly shows and Netflix's darker offerings -- but expect some drama for investors.
How to Play the Viacom/CBS Deal, Should There Even Be a Deal
Only at a discount, so if there is disappointment there is some wiggle room for maneuver.
Viacom Creates 2 Interesting Chart Patterns to Keep Traders on Edge
The technical signs do not instill a ton of confidence, though a bit of strength could change the outlook.
Viacom Stock Pops as Media Merger with CBS Set to Close
Viacom shareholders may finally be rewarded this week for their patience.
Why Wall Street Is Still Riding With Uber
Uber's crash on earnings does not mean the stock is totaled according to analysts covering the stock.
Wall Street Says Disney Should Still Be a Winning Stock
Disney's dive after earnings could open up a buying opportunity to investors that missed the recent run.
Tyson Foods Doesn't Turn Tail in Perilous Market After Earnings
The food giant is one of the few stocks holding its ground on Monday morning; here's why.